Sichuan Biokin Pharmaceutical Co., Ltd.SSE: 688506

Earnings Preannouncement for 2025

Jan 31, 2026 · Issued by Sichuan Biokin Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Jan 31, 2026

On 6ix: 6ix.com/news/earnings-preannouncement-for-2025-327

Earnings Preannouncement for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix

Earlier from Sichuan Biokin Pharmaceutical

Notice on Convening the 1st Extraordinary General Meeting in 2026Jan 24
Announcement on Voluntary Disclosure of Acceptance of the Marketing Application for iza-bren (EGFR×HER3 dual-antibody ADC) for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell CarcinomaJan 21
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% SharesJan 17
Biokin to Present at J.P. Morgan's 44th Annual Healthcare ConferenceJan 13
Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma into the Priority Review ProgramJan 7

Later from Sichuan Biokin Pharmaceutical

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Feb 10
Announcement on Resignation of the Secretary of Board of Directors and Assumption of the Secretary's Duties by Directors and Senior Management MembersFeb 14
Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer Meeting the Primary EndpointFeb 24
Announcement on Preliminary Earnings Estimate for 2025Feb 28
Announcement on Progress in Repurchasing SharesMar 4

All Sichuan Biokin Pharmaceutical news releases

Follow Sichuan Biokin Pharmaceutical into a list and get an email when it puts out news.

Follow Sichuan Biokin Pharmaceutical